Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

By
Andrea Surnit
June 10, 2026
4 min

Conexiant

At a Glance

Category	Detail
Condition	Obesity without diabetes
Key Mechanisms	Subcutaneous administration of survodutide
Target Population	Adults with a BMI of at least 30 or at least 27 with obesity-related complications, excluding diabetes
Care Setting	Clinical trial across multiple sites

Key Highlights

Survodutide led to greater weight loss compared to placebo over 76 weeks.
73% of patients on 3.6 mg and 72% on 6.0 mg achieved at least 5% weight loss.
Significant reductions in waist circumference and fat volume were observed.
Adverse gastrointestinal events were the primary safety concern.
No mortality was reported during the trial.

Guideline-Based Recommendations

Diagnosis

Patients must have a BMI of at least 30 or at least 27 with obesity-related complications.

Management

Survodutide titrated to 3.6 mg or 6 mg once weekly in conjunction with dietary counseling.

Monitoring & Follow-up

Monitor for gastrointestinal adverse events and weight loss progress.

Risks

Higher incidence of nausea, vomiting, diarrhea, and constipation compared to placebo.

Patient & Prescribing Data

725 patients enrolled in the SYNCHRONIZE-1 trial.

Weight loss of at least 15% was achieved by 36% and 46% of patients on 3.6 mg and 6.0 mg, respectively.

Clinical Best Practices

Consider patient eligibility carefully, excluding those with diabetes and uncontrolled hypertension.
Provide counseling on a reduced-calorie diet and physical activity alongside treatment.